Tenecteplase Reperfusion Therapy in Acute Ischemic Cerebrovascular Events-Ⅱ
Status:
Recruiting
Trial end date:
2023-10-31
Target enrollment:
Participant gender:
Summary
A Phase Ⅲ, Multicenter, Prospective, Randomized, Open Label, Blinded-endpoint (PROBE)
Controlled Trial of Recombinant Human TNK Tissue-type Plasminogen Activator (rhTNK-tPA) for
Injection Versus Alteplase for Acute Ischemic Stroke Within 4.5 Hours